Hydroxypropyl beta cyclodextrin adjuvanted influenza split vaccine - Kitasato Daiichi Sankyo Vaccine

Drug Profile

Hydroxypropyl beta cyclodextrin adjuvanted influenza split vaccine - Kitasato Daiichi Sankyo Vaccine

Alternative Names: HP-beta-CyD-adjuvanted influenza split vaccine

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kitasato Daiichi Sankyo Vaccine
  • Class Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 08 Sep 2017 Preclinical trials in Influenza virus infections in Japan before September 2017 (SC)
  • 08 Sep 2017 Kitasato-Daiichi Sankyo Vaccine plans a phase I trial for Influenza virus infections (Prevention) in Japan (UMIN000028530)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top